Management of renal disorders
1993; Wiley; Volume: 8; Issue: 4 Linguagem: Holandês
10.1002/jca.2920080407
ISSN1098-1101
AutoresRonald O. Gilcher, Ronald G. Strauss, David Ciavarella, Duke O. Kasprisin, D Kiprov, Harvey G. Klein, Bruce C. McLeod,
Tópico(s)Platelet Disorders and Treatments
ResumoJournal of Clinical ApheresisVolume 8, Issue 4 p. 258-269 Article Management of renal disorders Ronald O. Gilcher M.D., Ronald O. Gilcher M.D. President and CEO, Oklahoma Blood Institute Adjunct Professor of Pathology and Clinical Associate Professor of Medicine University of Oklahoma College of MedicineSearch for more papers by this authorRonald G. Strauss M.D., Ronald G. Strauss M.D. Professor of Pathology and Pediatrics, University of Iowa College of Medicine Medical Director, DeGowin Blood Center, University of Iowa Hospitals and Clinics Iowa City, IowaSearch for more papers by this authorDavid Ciavarella M.D., David Ciavarella M.D. Vice President, New York Blood Center Associate Professor of Pathology, New York Medical College Valhalla, New YorkSearch for more papers by this authorDuke O. Kasprisin M.D., Duke O. Kasprisin M.D. Principal Officer, American Red Cross Blood Services Vermont/New Hampshire Region Burlington, VermontSearch for more papers by this authorDobri D. Kiprov M.D., Dobri D. Kiprov M.D. Division of Immunotherapy, Department of Medicine, California Pacific Medical Center San Francisco, CaliforniaSearch for more papers by this authorHarvey G. Klein M.D., Harvey G. Klein M.D. Department of Transfusion Medicine, Warren G. Magnuson Clinical Center National Institutes of Health Bethesda, MarylandSearch for more papers by this authorBruce C. McLeod M.D., Bruce C. McLeod M.D. Professor of Medicine and Pathology, Rush Medical College Director Apheresis Unit, Associate Director Blood Center Rush-Presbyterian-St. Luke's Medical Center Chicago, IllinoisSearch for more papers by this author Ronald O. Gilcher M.D., Ronald O. Gilcher M.D. President and CEO, Oklahoma Blood Institute Adjunct Professor of Pathology and Clinical Associate Professor of Medicine University of Oklahoma College of MedicineSearch for more papers by this authorRonald G. Strauss M.D., Ronald G. Strauss M.D. Professor of Pathology and Pediatrics, University of Iowa College of Medicine Medical Director, DeGowin Blood Center, University of Iowa Hospitals and Clinics Iowa City, IowaSearch for more papers by this authorDavid Ciavarella M.D., David Ciavarella M.D. Vice President, New York Blood Center Associate Professor of Pathology, New York Medical College Valhalla, New YorkSearch for more papers by this authorDuke O. Kasprisin M.D., Duke O. Kasprisin M.D. Principal Officer, American Red Cross Blood Services Vermont/New Hampshire Region Burlington, VermontSearch for more papers by this authorDobri D. Kiprov M.D., Dobri D. Kiprov M.D. Division of Immunotherapy, Department of Medicine, California Pacific Medical Center San Francisco, CaliforniaSearch for more papers by this authorHarvey G. Klein M.D., Harvey G. Klein M.D. Department of Transfusion Medicine, Warren G. Magnuson Clinical Center National Institutes of Health Bethesda, MarylandSearch for more papers by this authorBruce C. McLeod M.D., Bruce C. McLeod M.D. Professor of Medicine and Pathology, Rush Medical College Director Apheresis Unit, Associate Director Blood Center Rush-Presbyterian-St. Luke's Medical Center Chicago, IllinoisSearch for more papers by this author First published: 1993 https://doi.org/10.1002/jca.2920080407Citations: 17Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M: Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 57: 775–788, 1974. 10.1016/0002-9343(74)90852-3 CASPubMedWeb of Science®Google Scholar 2 Bloch KJ: Cryoglobulinemia and hepatitis C virus. N Engl J Med 327: 1521–1522, 1992. 10.1056/NEJM199211193272111 CASPubMedWeb of Science®Google Scholar 3 Agnello V, Chung RT, Kaplan LM: A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327: 1490–1495, 1992. 10.1056/NEJM199211193272104 CASPubMedWeb of Science®Google Scholar 4 D'Amico G, Colasanti G, Ferrario F, et al.: Renal involvement in essential mixed cryoglobulinemia. Kidney Int 35: 1004, 1989. 10.1038/ki.1989.84 CASPubMedWeb of Science®Google Scholar 5 Gorevic PD, Kassab HJ, Levo Y, et al.: Mixed-cryoglobulinemia: clinical aspects and long term followup of 40 patients. Am J Med 69: 287–308, 1980. 10.1016/0002-9343(80)90390-3 PubMedWeb of Science®Google Scholar 6 Balow JE, Austin HA, Tsokos GC: Plasmapheresis therapy in immunologically mediated rheumatic and renal diseases. Clin Immunol Rev 3: 235–272, 1984. CASPubMedGoogle Scholar 7 Durand JM, Lefevre P, Harle JR, Boucrat J, Vitvitsky L, Soubeyrand J: Cutaneous vasculitis and cryoglobulinemia type II associated with hepatitis C virus infection. Lancet 337: 499–500, 1991. 10.1016/0140-6736(91)93443-D CASPubMedWeb of Science®Google Scholar 8 Geltner D, Kohn RW, Gorevic PD, et al.: The effect of combination therapy (steroids, immunosuppressives and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular imvolvement. Arthritis Rheum 24: 1121–1127, 1981. 10.1002/art.1780240902 PubMedWeb of Science®Google Scholar 9 Stratta P, Messina M, Valluri P, et al.: Plasma exchange in immune complex glomerulonephritis: clinical and immunological correlations. Int J Artif Organs 1: 27–29, 1983. Google Scholar 10 Berkman EM, Orlin JB: Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia. Transfusion 20: 171–178, 1980. 10.1046/j.1537-2995.1980.20280169957.x CASPubMedWeb of Science®Google Scholar 11 Ginder PA, Middendorg DE, Abdou NI: Pancytopenia with mixed cryoglobulinemia: evidence for anti-precursor cell activity of cryoglobulin—effects of plasmapheresis. J Clin Immunol 2: 55–58, 1982. 10.1007/BF00915979 PubMedWeb of Science®Google Scholar 12 Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L: Longterm results of therapy with interferon-a for type II essential mixed cryoglobulinemia. Blood 78: 3142–3147, 1991. PubMedWeb of Science®Google Scholar 13 Knox TA, Hillyer CD, Kaplan MM, Berkman EM: Mixed cryoglobulinemia responsive to interferon. Am J Med 91: 554–555, 1991. 10.1016/0002-9343(91)90196-5 PubMedWeb of Science®Google Scholar 14 Geltner D: Therapeutic approaches in mixed cryoglobulinemia. Springer Semin Immunopathol 10: 103–113, 1988. 10.1007/BF02054027 CASPubMedWeb of Science®Google Scholar 15 Ferri C, Gremignai G, Bombardieri S, Moriconi L, Pontrandolfo A, Vitali C, et al.: Plasma-exchange in mixed cryoglobulinemia. Effects on renal, liver, and neurologic involvement. La Ricerca Clin Lab 16: 403–411, 1986. CASWeb of Science®Google Scholar 16 Ferri C, Moriconi L, Gremignai G, Migliorini P, Paleologo G, Fosella PV, et al.: Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephrologie 43: 246–253, 1986. PubMedWeb of Science®Google Scholar 17 Schifferli JA, Berclaz R, Ryser JE, Blanc E: Neutropenia in a patient with essential cryoglobulinemia type 1: rapid reversal by plasmapheresis. Am J Med 86: 139–140, 1989. 10.1016/0002-9343(89)90253-2 PubMedWeb of Science®Google Scholar 18 Boom BW, Brand A, Bavinck JN, Eernisse JG, Daha MR, Vermeer BJ: Severe leukocytoclastic vasculitis of the skin in a patient with essential cryoglobulinemia treated with high-dose y-globulin intravenously. Arch Dermatol 124: 1550–1553, 1988. 10.1001/archderm.124.10.1550 CASPubMedWeb of Science®Google Scholar References 1 Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al.: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328: 465–470, 1993. 10.1056/NEJM199302183280703 CASPubMedWeb of Science®Google Scholar 2 Appel GB: Immune-complex glomerulonephritis — deposits plus interest. N Engl J Med Editorials 328: 505–506, 1993. 10.1056/NEJM199302183280711 CASPubMedWeb of Science®Google Scholar 3 Couser WG: Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 11: 449, 1988. 10.1016/S0272-6386(88)80079-9 CASPubMedWeb of Science®Google Scholar 4 Briggs WA, Johnson JP, Teichman S, et al.: Anti-glomerular basement membrane antibody mediated glomerulonephritis and Goodpasture's Syndrome. Medicine (Baltimore) 58: 348, 1979. 10.1097/00005792-197909000-00002 PubMedWeb of Science®Google Scholar 5 Beirne GJ, Wagnild JP, Zimmerman SW, et al.: Idiopathic crescentic glomerulonephritis. Medicine (Baltimore) 56: 349, 1977. 10.1097/00005792-197709000-00001 PubMedWeb of Science®Google Scholar 6 Lewis EJ, Schwartz MN: Idiopathic crescentic glomerulonephritis. Semin Nephrol 2: 193, 1982. Web of Science®Google Scholar 7 Scully RE, Mard EJ, McNeely WF, McNeely BU: Case records of the Massachusetts General Hospital (16-1993). N Engl J Med 328: 1183–1190, 1993. PubMedGoogle Scholar 8 Wilson CB, Dixon FJ: Anti-glomerular basement antibody-induced glomerulonephritis. Kidney Int 3: 74–89, 1973. 10.1038/ki.1973.14 CASPubMedWeb of Science®Google Scholar 9 Frasca GM, Zoumparidis NG, Borgnino LC, Neri L, Vangelista A, Bonomini V: Plasma exchange treatment in rapidly progressive glomerulonephritis associated with anti-neutrophil cytoplasmic autoantibodies. Int J Artif Organs 3: 181–184, 1992. Google Scholar 10 Balow JE: Plasmapheresis: development and application in treatment of renal disorders. Int J Artif Organs 10 (4): 324–330, 1986. 10.1111/j.1525-1594.1986.tb02572.x PubMedWeb of Science®Google Scholar 11 Cole E: Plasma exchange in rapidly progressive glomerulonephritis, Prog Clin Bio Res 337: 257–262, 1990. PubMedGoogle Scholar 12 Lockwood CM, Boulton-Jones JM, Jowenthal RM, et al.: Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis, BMJ 2: 252–254, 1975. 10.1136/bmj.2.5965.252 CASPubMedWeb of Science®Google Scholar 13 Pusey CD, Lockwood CM, Peters DK: Plasma exchange and immunosuppressive drugs in the treatment of glomerulonephritis due to antibodies to the glomerular basement membrane. Int J Artif Organs 6: 15–18, 1983. PubMedWeb of Science®Google Scholar 14 Kincaid-Smith P, d'Apice AJF: Plasmapheresis in rapidly progressive glomerulonephritis. Am J Med 65: 564–567, 1978. 10.1016/0002-9343(78)90840-9 PubMedWeb of Science®Google Scholar 15 Erickson SB, Kurtz SB, Donadio JV, et al.: Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome. Mayo Clin Proc 54: 714–720, 1979. CASPubMedWeb of Science®Google Scholar 16 Johnson JP, Whitman W, Briggs WA, et al.: Plasmapheresis and immunosuppressive agents in antibasement membrane antibody induced Goodpasture's syndrome. Am J Med 64: 354–359, 1978. 10.1016/0002-9343(78)90065-7 CASPubMedWeb of Science®Google Scholar 17 Hind CR, Lockwood CM, Peters DK, et al.: Prognosis after immunosuppression of patients with crescentic glomerulonephritis requiring dialysis. Lancet 1: 263, 1983. 10.1016/S0140-6736(83)91685-9 PubMedWeb of Science®Google Scholar 18 Oredugba O, Mazumdar DC, Meyer JS, et al.: Pulse methylprednisolone therapy in idiopathic, rapidly progressive glomerulonephritis. Ann Intern Med 92: 504, 1980. 10.7326/0003-4819-92-4-504 PubMedWeb of Science®Google Scholar 19 Glockner WM, Sieberth HG, Wichmann HE, Backes E, Bambanci R, Boesken WH, et al.: Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-centre study. Clin Nephrol 29: 1–8, 1988. PubMedWeb of Science®Google Scholar 20 Johnson JP, Moore J, Austin HA, et al.: Therapy of anti-glomerular basement membrane antibody disease: analysis on the prognostic significance of clinical, pathologic, and treatment factors. Medicine (Baltimore) 64: 219–227, 1985. 10.1097/00005792-198507000-00003 PubMedWeb of Science®Google Scholar 21 Wing EJ, Bruns FJ, Fraley DS, et al.: Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 244: 2423, 1980. PubMedWeb of Science®Google Scholar 22 Bruns FJ, Adler S, Fraley DS, et al.: Long-term follow-up of aggressively treated idiopathic rapidly progressive glomerulonephritis. Am J Med 86: 400, 1989. 10.1016/0002-9343(89)90336-7 CASPubMedWeb of Science®Google Scholar References 1 Remuzzi G, Tognoni G: Thrombotic thrombocytopenic purpura (TTP) and haemolytic uraemic syndrome (HUS): a clinical pule or a methodological challenge?. J Nephrol 2: 77, 1989. Google Scholar 2 Sibai B, et al.: Maternal perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in several preeclampsia eclampsia. Am J Obstet Gynecol 155: 501–509, 1986. 10.1016/0002-9378(86)90266-8 CASPubMedWeb of Science®Google Scholar 3 Ridolfi RL, Bell WR: Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine (Baltimore) 60: 413, 1981. 10.1097/00005792-198111000-00003 CASPubMedWeb of Science®Google Scholar 4 Crain SM, Choudhury AM: Thrombotic thrombocytopenic purpura: a reappraisal. JAMA 246: 1243, 1981. 10.1001/jama.246.11.1243 CASPubMedWeb of Science®Google Scholar 5 Spencer CD, Crane FM, Kumar JR, et al.: Treatment of postpartum hemolytic uremic syndrome with plasma exchange. JAMA 247: 2808–2809, 1982. 10.1001/jama.247.20.2808 CASPubMedWeb of Science®Google Scholar 6 Niessenson AR, Krumlovsky FA, del Greco F: Postpatum hemolytic uremic syndrome: late recovery after prolonged maintenance dialysis. JAMA 242: 173, 1979. 10.1001/jama.242.2.173 PubMedWeb of Science®Google Scholar 7 Brain MC, Neame PB: Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Semin Thromb Hemost 8: 186, 1982. 10.1055/s-2007-1005051 CASPubMedWeb of Science®Google Scholar 8 Burns ER, Zucker-Franklin D: Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 60: 1030, 1982. PubMedWeb of Science®Google Scholar 9 Marcus AJ: Moschowitz revisited (editorial). N Engl J Med 307: 1447, 1982. 10.1056/NEJM198212023072311 CASPubMedWeb of Science®Google Scholar 10 Byrnes JJ, Moake JL, Klug P, Periiman P: Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 34: 169–174, 1990. 10.1002/ajh.2830340303 PubMedWeb of Science®Google Scholar 11 Moak JL, Rudy CK, Troll H, et al.: Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. Blood 69: 924, 1987 PubMedWeb of Science®Google Scholar 12 Kwaan HC: Thrombotic thrombocytopenic purpura (editorial). JAMA 247: 3119, 1982. 10.1001/jama.247.22.3119 PubMedWeb of Science®Google Scholar 13 Onundarson PT, Rowe JM, Heal JM, Francis CW: Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. Arch Intern Med 152: 791–796, 1992. PubMedWeb of Science®Google Scholar 14 Obrador GT, Ziegler ZR, Shadduck RK, Rosenfeld CS, Hanrahan JB: Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 42: 217–220, 1993. 10.1002/ajh.2830420214 PubMedWeb of Science®Google Scholar 15 Bell WR, Braine HG, Ness PM, Kickler TS: Improved survival in thrombotic thrombocytopenic purpura—hemolytic uremic syndrome. N Engl J Med 325: 398–403, 1991. 10.1056/NEJM199108083250605 PubMedWeb of Science®Google Scholar 16 Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al.: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325: 393–397, 1991. 10.1056/NEJM199108083250604 CASPubMedWeb of Science®Google Scholar 17 Moake JL: TTP—desperation, empiricism, progress. N Engl J Med 325: 426–428, 1991. 10.1056/NEJM199108083250611 CASPubMedWeb of Science®Google Scholar 18 Gilcher RO: Refractory TTP responding to I.V. gamma globulin. Blood 64: 237, 1985 (abstract). Google Scholar 19 Finazzi G, Bellavita P, Falanga A, Viero P, Barbui T: Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Am J Hematol 41: 165–169, 1992. 10.1002/ajh.2830410305 CASPubMedWeb of Science®Google Scholar 20 Dolislager D, Tune B: The hemolytic-uremic syndrome: spectrum of severity and significance of prodrome. Am J Dis Child 132: 55, 1978. 10.1001/archpedi.1978.02120260057014 CASPubMedWeb of Science®Google Scholar 21 Thysell H, Oxelius VA, Norlin M: Successful treatment of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura with fresh frozen plasma and plasma exchange. Acta Med Scand 212: 285, 1982. 10.1111/j.0954-6820.1982.tb03215.x CASPubMedWeb of Science®Google Scholar 22 Misiani R, Mecca G, Remuzzi G: Haemolytic uraemic syndrome: therapeutic effect of plasma infusion (letter). BMJ 286: 147, 1983. 10.1136/bmj.286.6359.148 PubMedWeb of Science®Google Scholar 23 Shumak KH, Rock GA: Medical progress: therapeutic plasma exchange. N Engl J Med 310: 762, 1984. 10.1056/NEJM198403223101206 PubMedWeb of Science®Google Scholar 24 Martin J, et al.: Plasma exchange for preaclampsia. Am J Obstet Gynecol 162: 126–137, 1990. 10.1016/0002-9378(90)90835-U PubMedWeb of Science®Google Scholar 25 Roberts AW, Gillett EA, Fleming SJ: Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: outcome with plasma exchange. J Clin Apheresis 6: 150–154, 1991. 10.1002/jca.2920060305 CASPubMedGoogle Scholar 26 Rock G, Shumak K, Kelton J, Blanchette VS, Buskard N, Nair R, et al.: Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 32: 710–714, 1992. 10.1046/j.1537-2995.1992.32893032096.x PubMedWeb of Science®Google Scholar References 1 Cohen DJ, Sherman WH, Osserman EF, et al.: Acute renal failure in patients with multiple myeloma. Am J Med 76: 247–256, 1984. 10.1016/0002-9343(84)90781-2 PubMedWeb of Science®Google Scholar 2 DeFronzo RA, Cooke CR, Wright JR, et al.: Renal function in patients with multiple myeloma. Medicine (Baltimore) 57: 151–166, 1978. 10.1097/00005792-197803000-00003 PubMedWeb of Science®Google Scholar 3 Bernstein SP, Humes HD: Reversible renal insufficiency in multi ple myeloma. Arch Intern Med 142: 2083–2086, 1986. 10.1001/archinte.142.12.2083 PubMedWeb of Science®Google Scholar 4 Hamblin TJ: The kidney in myeloma. BMJ 2: 292, 1986. Google Scholar 5 Solomon A, Weiss DT, Kattine AA: Nephrotoxic potential of Bonce-Jones proteins. N Engl J Med 324: 1845–1851, 1991. 10.1056/NEJM199106273242603 PubMedWeb of Science®Google Scholar 6 Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma. Arch Intern Med 150: 1693–1695, 1990. 10.1001/archinte.1990.00040031693017 CASPubMedWeb of Science®Google Scholar 7 Bachrach HJ, Myers JB, Bartholomew WR: A unique case of kappa light-chain disease associated with cryoglobulinemia, pyroglobulinemia, and hyperviscosity syndrome. Am J Med 86: 596–602, 1989. 10.1016/0002-9343(89)90393-8 CASPubMedWeb of Science®Google Scholar 8 Carter PW, Cohen HJ, Crawford J: Hyperviscosity syndrome in association with kappa light chain myeloma. Am J Med 86: 591–595, 1989. 10.1016/0002-9343(89)90392-6 PubMedWeb of Science®Google Scholar 9 Bergsagel DE: Plasma cell myeloma. In WJ Williams, E Beutler, AJ Ersler, MA Lichtman (ed): “ Hematology,” 4th edition. New York: McGraw Hill Publishing Company, 1990, chapter 122, pp 1114–1141. Google Scholar 10 McGrath MA, Penny R: Paraproteinemias. Blood hyperviscosity and clinical manifestation. J Clin Invest 58: 1155–1162, 1976. 10.1172/JCI108568 CASPubMedWeb of Science®Google Scholar 11 Bergsagel DE: Macroglobulinemia. In WJ Williams, E Beutler, AJ Ersler, MA Lichtman (ed): “ Hematology,” 4th edition. New York: McGraw Hill Publishing Company, 1990, chapter 123, pp 1141–1145. Google Scholar 12 Misiani R, Tiraboschi G, Mingardi G, Mecca G: Management of myeloma kidney: an anti-light chain approach. Am J Kidney Dis 10: 28–33, 1987. 10.1016/S0272-6386(87)80007-0 CASPubMedWeb of Science®Google Scholar 13 Russell JA, Fitzharris BM, Corringham, et al.,: Plasma exchange versus peritoneal dialysis for removing Bence-Jones protein. BMJ 2: 1397, 1978. 10.1136/bmj.2.6149.1397 CASPubMedWeb of Science®Google Scholar 14 Bear RA, Cole EH, Slang A, et al.: Treatment of acute renal failure due to myeloma kidney. Can Med Assoc J 123: 750–753, 1980. PubMedWeb of Science®Google Scholar 15 Johnson WJ, Kyle RA, Dahlberg PJ: Dialysis in the treatment of multiple myeloma. Mayo Clin Proc 55: 65–72, 1980. CASPubMedWeb of Science®Google Scholar 16 Solling K, Solling J: Clearances of Bence-Jones proteins during peritoneal dialysis or plasmapheresis in myelomatosis associated with renal failure. Contr Nephrol 68: 259–262, 1988. 10.1159/000416523 CASPubMedGoogle Scholar 17 Reinhart WH, Lutolf O, Nydegger U, Mahler F, Straub PW: Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenstrom and multiple myeloma: influence on blood rheology and the microcirculation. J Lab Clin Med 119: 69–76, 1992. CASPubMedWeb of Science®Google Scholar 18 Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE: Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150: 863–869, 1990. 10.1001/archinte.1990.00390160111022 CASPubMedWeb of Science®Google Scholar 19 Wahlin A, Lofvenberg E, Holm J: Improved survival in multiple myeloma with renal failure. Acta Med Scand 221: 205–209, 1987. 10.1111/j.0954-6820.1987.tb01268.x PubMedWeb of Science®Google Scholar References 1 Rose EA, Barr ML, Xu H, Pepino P, Murphy MP, McGovern MA, et al.: Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant 11: 746–750, 1992. CASPubMedWeb of Science®Google Scholar 2 Nordin MRC, Hubbell EA, O'Sullivan EJ, Johnson MR, Mullen GM, Heroux AL, et al.: Successful treatment of heart transplant rejection with photopheresis. Transplantation 53: 808–815, 1992. 10.1097/00007890-199204000-00021 PubMedWeb of Science®Google Scholar 3 Nordin MRC, Hubbell EA, O'Sullivan EJ, Johnson MR, Mullen GM, Heroux AL, et al.: Photopheresis versus corticosteroids in the therapy of heart transplant rejection. Circulation (Suppl II) 86: 242–250, 1992. Google Scholar 4 Partanen J, Nieminen MS, Krogerus L, Harjula ALJ, Mattila S: Heart transplant rejection treated with plasmapheresis. J Heart Lung Transplant 11: 301–305, 1992. CASPubMedWeb of Science®Google Scholar References 1 Storm TB, Tilney NL: Immunobiology and immunopharmacology of graft rejection. In RW Schrier, CW Gottschalk (eds): “ Discases of the Kidney,” 4th ed. Boston: Little, Brown & Co., 1988, p 3177. Google Scholar 2 Braun WE: The immunobiology of different types of renal allograft rejectioln. In EL Milford, BM Brenner, JH Stein (eds): “ Contemporary Issues in Nephrology” New York: Churchill Livingstone, 1989, p 45. Google Scholar 3 Backman U, Fellstrom B, Frodin L, Sjoberg O, Tufveson G, Wikstrom B: Successful transplantation in highly sensitized patients. Transplant Proc 21: 762–763, 1989. CASPubMedWeb of Science®Google Scholar 4 Palmer A, Welsh K, Gjorstrup P, Taube D, Bewick M, Thick M: Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 8628: 10–12, 1989. 10.1016/S0140-6736(89)91672-3 Google Scholar 5 Cardella CJ, Pei Y, Brady HR: ABO blood group incompatible kidney transplantation: a case report and review of the literature. Clin Nephrol 28 (6): 295–299, 1987. PubMedWeb of Science®Google Scholar 6 Kupin WL, Venkat KK, Hayashi H, Mozes MF, Oh HK, Watt R: Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients. Transplantation 51: 324–329, 1991. 10.1097/00007890-199102000-00010 PubMedWeb of Science®Google Scholar 7 Taube D, Palmer A, Welsh K, Bewick M, Snowden S, Thick M: Removal of anti-HLA antibodies prior to transplantation: an effective and successful strategy for highly sensitized renal allograft recipients. Transplant Proc 21: 694–695, 1989. PubMedWeb of Science®Google Scholar 8 Gjorstrup P, Watt RM: Therapeutic protein A immunoadsorption. A review. Transfus Sci 11: 281–302, 1990. 10.1016/0955-3886(90)90028-H Web of Science®Google Scholar 9 Hakim RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM: Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 16: 423–431, 1990. 10.1016/S0272-6386(12)80054-0 CASPubMedWeb of Science®Google Scholar 10 Fassbinder W, Scheuermann EH, Stutte HJ, et al.: Improved graft prognosis by treatment of steroid resistant rejections with ATG and plasmapheresis. Proc Eur Dia Transplant Assoc 20: 362–367, 1983. CASPubMedWeb of Science®Google Scholar 11 Adams MB, Kauffman HM, Hussey CV, et al.: Plasmapheresis in the treatment of refractory renal allograft rejection. Transplant Proc 13: 491–494, 1981. PubMedWeb of Science®Google Scholar 12 Gelfand MC, Helfrich GB, Peters SM, et al.: Extracorporeal immunomodulation (EIM) by plasmaleukapheresis (PLP) in the treatment of steroid resistant renal rejection. Trans Am Soc Artif Intern Organs 29: 339–343, 1983. PubMedWeb of Science®Google Scholar 13 Stegmayr B, Svalander C, Persson H: Reversal of kidney transplant rejection after plasmalymphocytapheresis. Transplant Proc 20: 455–456, 1988. PubMedWeb of Science®Google Scholar Citing Literature Volume8, Issue4Special Issue: Clinical Applications of Therapeutic Hemapheresis1993Pages 258-269 ReferencesRelatedInformation
Referência(s)